Sinopharm (BBIBP-CorV) COVID-19 Vaccination in Hemodialysis Patients and Healthy Individuals: 1-year Effectiveness and Immunogenicity Immunization of Sinopharm Vaccine against COVID-19
Main Article Content
Abstract
Introduction: The COVID-19 pandemic has presented significant challenges for immunocompromised populations, particularly hemodialysis patients, who are at an elevated risk for severe outcomes. Vaccination remains a critical strategy to mitigate these risks. This study evaluates the 1-year effectiveness and immunogenicity of the Sinopharm (BBIBP-CorV) COVID-19 vaccine in hemodialysis patients compared to healthy individuals, exploring correlations between dialysis parameters and vaccine-induced immunity.
Methods: This study was conducted according to the ethical principles outlined in the Declaration of Helsinki and approved by the Institutional Review Board of Shahid Beheshti University of Medical Sciences. Participants included 87 hemodialysis patients and 29 healthy controls who received two doses of the Sinopharm vaccine with a 28–30-day interval. Data were collected through in-person interviews and follow-up phone interviews at 2-, 6-, and 12-months post-vaccination. Blood samples were taken at specified intervals to measure humoral and cellular immune responses, including Anti Spike Antibody IgG, Anti receptor-binding domain(RBD) total, neutralizing antibodies, and COVID-19 interferon gamma release assay( IGRA).
Results: A total of 87 hemodialysis patients (68.97% male, mean age 53.32±15.54 years) and 29 healthy controls (27.59% male, mean age 35.72±6.19 years) were included. There was no significant difference in breakthrough infection and its severity among the groups. Breakthrough infections were observed in 5.75% of hemodialysis cases and 17.24% of healthy controls, with hemodialysis not significantly elevating the risk (P=0.08; HR: 0.34; 95% CI: 0.1, 1.16). None of the markers of immune response was associated with breakthrough infection. There was a moderate correlation between Anti-Spike and IGRA level in patients receiving the third dose.
Conclusion: The Sinopharm COVID-19 vaccine demonstrated effectiveness and induced significant immunogenicity in both hemodialysis patients and healthy individuals, with booster doses enhancing long-term immunity. This study underscores the importance of booster vaccinations in maintaining immunity, especially in immunocompromised populations.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus (COVID-19) vaccinations. Our World in Data. Published 2020. Accessed April 28, 2023. https://ourworldindata.org/covid-vaccinations
3. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200. Published 2022 May 23. doi:10.1186/s12916-022-02397-y
4. Owusu KA, Effendi MK, Thompson Bastin ML, Tirmizi S, Lat I, Ammar MA. Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations. Hospital Pharmacy. 2022;57(4):575-587. doi:10.1177/00185787211066463
5. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526-1533. doi:10.2215/CJN.00950208
6. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5): 440-451. doi:10.1111/j.1525-139X.2007.00283.x.
7. Butler AM, Layton JB, Dharnidharka VR, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis. Am J Kidney Dis. 2020;75(1):72-83. doi:10.1053/j.ajkd.2019.05.018.
8. Calisti G, Herman O, Powley M, Haque T. Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster. BMJ Case Rep. 2014;2014:bcr2013202191. Published 2014 Jun 10. doi:10.1136/bcr-2013-202191.
9. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020;16:705-706. doi:10.1038/s41581-020-00349-4
10. Falahi S, Sayyadi H, Kenarkoohi A. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis. Health Sci Rep. 2022;5(6):e874. Published 2022 Oct 3. doi:10.1002/hsr2.874
11. Clemens J, Aziz AB, Tadesse BT, Kang S, Marks F, Kim J. Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries. EClinicalMedicine. 2022; 43:101253. doi:10.1016/j.eclinm.2021.101253.
12. Peiyao R, Mengjie Y, Xiaogang S, et al. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis. Front Public Health. 2022;10:95109 6. Published 2022 Sep 23. doi:10.3389/fpubh.2022.951096.
13. Kliger AS, Silberzweig J. COVID-19 and Dialysis Patients: Unsolved Problems in Early 2021. J Am Soc Nephrol. 2021;32(5):1018-1020. doi:10.1681/ASN.2020121766.
14. Martins MP, de Oliveira RB. COVID-19 and chronic kidney disease: a narrative review. COVID. 2023;3(8):1092-1105. doi:10.3390/covid3080080.
15. Brkovic V, Nikolic G, Baralic M, et al. A Study on Mortality Predictors in Hemodialysis Patients Infected with COVID-19: Impact of Vaccination Status. Vaccines (Basel). 2023;12(1):2. Published 2023 Dec 19. doi:10.3390/vaccines12010002.
16. Wand O, Nacasch N, Fadeela A, et al. Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. J Nephrol. 2022;35:1479-1487. doi:10.1007/s40620-022-01245-9.
17. Broseta JJ, Rodríguez-Espinosa D, Cuadrado E, Rodríguez N, Bedini JL, Maduell F. Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients. Vaccines (Basel). 2022;10(4):522. Published 2022 Mar 27. doi:10.3390/vaccines10040522.
18. Campo S, Lacquaniti A, Trombetta D, Smeriglio A, Monardo P. Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin. J Clin Med. 2022;11 (13):3759. Published 2022 Jun 28. doi:10.3390/jcm11133759.
19. Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front Immunol. 2023;14:1055 457. Published 2023 Jan 19. doi:10.3389/fimmu.2023.1055457.
20. Yau K, Abe KT, Naimark D, et al. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis [published correction appears in JAMA Netw Open. 2022 Feb 1;5(2):e221422. doi: 10.1001/jamanetworkopen.2022.1422]. JAMA Netw Open. 2021;4(9):e2123622. Published 2021 Sep 1. doi:10.1001/jamanetworkopen.2021.23622.
21. Yoshifuji A, Toda M, Oyama E, et al. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients. Clin Exp Nephrol. 2024;28(7):674-682. doi:10.1007/s10157-024-02477-8.
22. Poli MC, Vial C, Rey-Jurado E, et al. A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients. Vaccines (Basel). 2023;11(5):1012. Published 2023 May 22. doi:10.3390/vaccines11051012.
23. Teisseyre M, Graça D, Re D, et al. Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease. Nephrol Dial Transplant. 2023;38(1):249-251. doi:10.1093/ndt/gfac294
24. Holt SG, Mahmoud S, Ahmed W, et al. An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates. Nephrology (Carlton). 2022;27(3):260-268. doi:10.1111/nep.13980.
25. Alirezaei A, Fazeli SA, Shafiei M, et al. Efficacy of Sinopharm® COVID-19 Vaccine in Hemodialysis Patients: A Preliminary Report. Iranian Journal of Kidney Diseases. 2022 Jul 1;16(4). doi:10.52547/ijkd.7024.
26. Nafar M, Chehrazi S, Dalili N, et al. Humoral immunity of BBIBP-CorV (Sinopharm) in kidney transplant recipients: Is it time to revise vaccination strategies. Transpl Infect Dis. 2022;24(2):e13798. doi:10.1111/tid.13798.
27. Bai S, Dhrolia M, Qureshi H, Qureshi R, Nasir K, Ahmad A. Comparison of COVID-19 Inactivated Virus Vaccine Immunogenicity Between Healthy Individuals and Patients on Hemodialysis: A Single-Center Study From Pakistan. Cureus. 2022;14(4):e2 4153. Published 2022 Apr 15. doi:10.7759/cureus.24153.